Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N02CD01

Aimovig(erenumab)

Migraine Disorders

Marketing Authorisation Holder: Novartis Europharm Limited

EMA Authorisation: 26/07/2018

INN: erenumab

Indication

Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Aimovig — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.